Oncolytics Biotech Inc.
NASDAQ:ONCYBiotechnology
+$0.03 today
- Market cap
- $50.41M
- Beta
- 1.08
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$0.32
Volume 0.38M
Average 1.26M
Returns on capital
Oncolytics Biotech Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
757.0%
avg 3773.9%
ROIC
-1716.0%
avg -269.1%
ROA
-379.3%
avg -120.0%
Analysis
ROE is currently the strongest return metric at 757.0% versus its period average of 3773.9%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Thomas C. Heineman | Chief Medical Officer | CAD 675.47K | 67 | — | — |
Jared Kelly | Chief Executive Officer & Director | CAD 582.15K | 40 | 114.05K | 0.11% |
Kirk J. Look | Chief Financial Officer | CAD 575.18K | 54 | — | — |
Allison Hagerman | Chief Technology Officer | CAD 343.8K | 42 | 115.06K | 0.11% |
John Mark Lievonen | Consultant | CAD 18.26K | — | — | — |
Yujun Wu | VP & Head of Biostatistics | — | — | — | — |
Jon Patton | Director of Investor Relations & Communication | — | — | — | — |
Andrew Aromando | Chief Business Officer | — | 56 | 55.10K | 0.05% |
John McAdory | Chief Operating Officer | — | 49 | — | — |
Compensation is shown in the reported currency; data updated Oct 3, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Mar 12, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
14
$362,615.06
Sells
0
$0.00
Net Transaction Value
+$362,615.06
Net buying
Most Active
Kelly Jared
3 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Mar 12, 26Mar 12, 2026 | Kelly Jared Direct | Buy | $4.8K$4,848.00 |
| Mar 11, 26Mar 11, 2026 | Parsons James T. Direct | Buy | $10.3K$10,300.00 |
| Feb 12, 26Feb 12, 2026 | Look Kirk Direct | Buy | $10.1K$10,104.00 |
| Feb 12, 26Feb 12, 2026 | Andrews Patricia S Direct | Buy | $30.3K$30,291.78 |
| Feb 12, 26Feb 12, 2026 | Kelly Jared Direct | Buy | $24.8K$24,839.00 |
| Feb 12, 26Feb 12, 2026 | Heineman Thomas Charles Direct | Buy | $10K$10,033.16 |
| Feb 12, 26Feb 12, 2026 | Brown Deborah Margaret Direct | Buy | $21.2K$21,240.00 |
| Feb 12, 26Feb 12, 2026 | Hagerman Allison Direct | Buy | $8.3K$8,298.00 |
| Feb 12, 26Feb 12, 2026 | Seizinger Bernd R. Direct | Buy | $33.9K$33,864.00 |
| Feb 12, 26Feb 12, 2026 | Pisano Wayne Direct | Buy | $25.3K$25,338.00 |
1–10 of 14
Summary
Insiders reported 14 buys worth $362,615.06 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $362,615.06. Kelly Jared was the most active insider with 3 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Oncolytics Biotech Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about ONCY's management, answered from reported figures.
Who manages ONCY?
Oncolytics Biotech Inc. (ONCY) lists 9 active executives. The top listed executive is Kirk J. Look, Chief Financial Officer.
Are ONCY insiders buying or selling?
Recent insider activity shows net buying of $362,615.06.
Continue the stock analysis
Jump to another research area for this company.